Inflammatory Indices and Schizophrenia Severity in the Mexican Population

Research into schizophrenia spectrum disorders (SSDs) is increasingly focusing on the role of immune-inflammatory activation. Recent studies have explored the use of complete blood count (CBC)-based inflammation indexes as cost-effective and reproducible markers to assess the inflammatory status and symptom severity of patients.

One such study, which included inpatients with SSDs aged 18-65 hospitalized between May 2020 and March 2024, investigated the relationship between specific inflammatory ratios and the severity of clinical symptoms. The researchers focused on three primary markers: the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the platelet-to-lymphocyte ratio (PLR).

Findings on Monocyte-to-Lymphocyte Ratio

The study utilized structural equation modelling (SEM) to analyze 266 participants, accounting for variables such as obesity, antipsychotic treatment, and substance use disorder. The analysis revealed a significant relationship between the monocyte-to-lymphocyte ratio (MLR) and the severity of both positive and negative symptoms.

Specifically, the MLR showed a coefficient of 0.19 (p=0.048) regarding positive symptoms and a coefficient of 0.27 (p=0.004) regarding negative symptoms. In contrast, the study found no significant relationship between symptom severity and either the neutrophil-to-lymphocyte ratio (NLR) or the platelet-to-lymphocyte ratio (PLR).

The findings suggest that the MLR may serve as a more precise indicator of symptom severity in individuals with SSDs than other CBC-based ratios.

Clinical Variables and Interactions

Beyond inflammatory markers, the SEM analysis identified other significant clinical links. The research showed a significant relationship between symptom severity and both antipsychotic treatment and substance use disorder.

the study noted a significant link between the use of antipsychotic treatment and obesity among the participants.

Broader Scientific Context

The pursuit of blood-based inflammatory indices is part of a larger effort to understand the pathophysiology of schizophrenia. Some research suggests that inflammation is involved in both the clinical manifestations and the underlying mechanisms of the disorder, positioning these indices as potential screening tools for inflammatory status.

However, the wider scientific literature on inflammatory blood-based markers in schizophrenia—including markers such as high-sensitivity C-reactive protein (hs-CRP)—has been described as large but inconsistent.

Study Limitations and Considerations

The researchers noted several limitations regarding their findings. The study employed a cross-sectional design, which provides a snapshot of data at one point in time rather than tracking changes over a duration.

the researchers acknowledged that the sample representativeness was somewhat limited. These factors mean that while a significant relationship was observed between MLR and symptom severity, the results should be viewed within the context of these constraints.